Comparison of Systemic and Renal Effects of Dopexamine and Dopamine in Norepinephrine-Treated Septic Shock

Journal of Cardiothoracic and Vascular Anesthesia

Volumn 20, Issue 2, 2006, Pages 173-178

  Schmoelz, Martin ^a   Schelling, Gustav ^a   Dunker, Martin ^a   Irlbeck, Michael ^a  

^a UNIVERSITY OF MUNICH   (Germany)

Author keywords

acute renal failure; dopexamine; norepinephrine; renal dose dopamine; septic shock

Indexed keywords

BETA ADRENERGIC RECEPTOR BLOCKING AGENT; DIURETIC AGENT; DOPAMINE; DOPEXAMINE; MONOAMINE OXIDASE INHIBITOR; NORADRENALIN; PLACEBO; VASODILATOR AGENT;

ADULT; AGED; ARTICLE; CAUSE OF DEATH; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CREATININE CLEARANCE; DOUBLE BLIND PROCEDURE; DRUG EFFECT; DRUG EFFICACY; FEMALE; HEART FAILURE; HEART RATE; HEMODYNAMICS; HEMOFILTRATION; HUMAN; INTENSIVE CARE UNIT; KIDNEY DISEASE; KIDNEY FAILURE; KIDNEY FUNCTION; MAJOR CLINICAL STUDY; MALE; POST HOC ANALYSIS; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; SEPTIC SHOCK; TERTIARY HEALTH CARE; UNIVERSITY HOSPITAL;

ADRENERGIC ALPHA-AGONISTS; CARDIOTONIC AGENTS; CREATINE; DOPAMINE; DOPAMINE AGONISTS; DOUBLE-BLIND METHOD; FEMALE; FOLLOW-UP STUDIES; HUMANS; KIDNEY; MALE; MIDDLE AGED; NOREPINEPHRINE; PROSPECTIVE STUDIES; SHOCK, SEPTIC; TREATMENT OUTCOME; VASOCONSTRICTION;

EID: 33645970747     PISSN: 10530770     EISSN: None     Source Type: Journal    
DOI: 10.1053/j.jvca.2005.10.016     Document Type: Article

References (36)

1. Riedemann N.C., Guo R.F., and Ward P.A. The enigma of sepsis. J Clin Invest 112 (2003) 460-467
2. Angus D.C., Linde-Zwirble W.T., Lidicker J., et al. Epidemiology of severe sepsis in the United States. Analysis of incidence, outcome, and associated costs of care. Crit Care Med 29 (2001) 1303-1310
3. D'Intini V., Ronco C., Bonello M., et al. Renal replacement therapy in acute renal failure. Best Pract Res Clin Anaesthesiol 18 (2004) 145-157
4. Landry D.W., and Oliver J.A. The pathogenesis of vasodilatory shock. N Engl J Med 345 (2001) 588-595
5. Bellomo R., May C., Wan L., et al. Acute renal failure and sepsis. N Engl J Med 351 (2004) 2347-2349
6. Galley H.F. Renal-dose dopamine. Will the message now get through?. Lancet 356 (2000) 2112-2113
7. Baguneid M.S., Welch M., Bukkari M., et al. Vascular surgical society of Great Britain and Ireland. Randomized double-blind study of dopexamine versus placebo in aortic surgery. Br J Surg 86 (1999) 698
8. Baguneid M.S., Welch M., Bukhari M., et al. A randomized study to evaluate the effect of a perioperative infusion of dopexamine on colonic mucosal ischemia after aortic surgery. J Vasc Surg 33 (2001) 758-763
9. Boyd O., Lamb G., Mackay C.J., et al. A comparison of the efficacy of dopexamine and dobutamine for increasing oxygen delivery in high-risk surgical patients. Anaesth Intensive Care 23 (1995) 478-484
10. Levy M.M., Fink M.P., Marshall J.C., et al. 2001 SCCM/ESICM/ACCP/ATS/SIS International Sepsis Definitions Conference. Crit Care Med 31 (2003) 1250-1256
11. Dickstein K. Diagnosis and assessment of the heart failure patient. The cornerstone of effective management. Eur J Heart Fail 7 (2005) 303-308
12. Vovan T., and Brenner M. Controversy. Is there a "renal-dose" dopamine?. Crit Care Med 28 (2000) 1220
13. Ichai C., Passeron C., Carles M., et al. Prolonged low-dose dopamine infusion induces a transient improvement in renal function in hemodynamically stable, critically ill patients. A single-blind, prospective, controlled study. Crit Care Med 28 (2000) 1329-1335
14. Juste R.N., Panikkar K., and Soni N. The effects of low-dose dopamine infusions on haemodynamic and renal parameters in patients with septic shock requiring treatment with noradrenaline. Intensive Care Med 24 (1998) 564-568
15. Thackray S., Easthaugh J., Freemantle N., et al. The effectiveness and relative effectiveness of intravenous inotropic drugs acting through the adrenergic pathway in patients with heart failure-A meta-regression analysis. Eur J Heart Fail 4 (2002) 515-529
16. Knaus W.A., and Draper E.A. APACHE II. A severity of disease classification system. Crit Care Med 13 (1985) 818-829
17. Vincent J.L., Moreno R., Takala J., et al. The SOFA (Sepsis-related Organ Failure Assessment) score to describe organ dysfunction/failure. On behalf of the Working Group on Sepsis-Related Problems of the European Society of Intensive Care Medicine. Intensive Care Med 22 (1996) 707-710
18. Briegel J., Forst F., Haller M., et al. Stress doses of hydrocortisone reverse hyperdynamic septic shock. A prospective, randomized, double-blind, single-center study. Crit Care Med 27 (1999) 723-732
19. Heindl B., Pollwein B., Schleutermann S., et al. Development of a knowledge base for automatic monitoring of renal function of intensive care patients over time. Comput Methods Programs Biomed 62 (2000) 1-10
20. Heritier S.R., Gebski V.J., and Keech A.C. Inclusion of patients in clinical trial analysis. The intention-to-treat principle. Med J Aust 179 (2003) 438-440
21. MacGregor D.A., Prielipp R.C., Black C.S., et al. Renal-dose dopamine does not alter the response to beta-adrenergic stimulation by isoproterenol in healthy human volunteers. Chest 112 (1997) 40-44
22. Fitton A., and Benfield P. Dopexamine hydrochloride. A review of its pharmacodynamic and pharmacokinetic properties and therapeutic potential in acute cardiac insufficiency. Drugs 39 (1990) 308-330
23. Ralph C.J., Tanser S.J., Macnaughton P.D., et al. A randomised controlled trial investigating the effects of dopexamine on gastrointestinal function and organ dysfunction in the critically ill. Intensive Care Med 28 (2002) 884-890
24. Levy B., Nace L., Bollaert P.E., et al. Comparison of systemic and regional effects of dobutamine and dopexamine in norepinephrine-treated septic shock. Intensive Care Med 25 (1999) 942-948
25. Berendes E., Mollhoff T., Van Aken H., et al. Effects of dopexamine on creatinine clearance, systemic inflammation, and splanchnic oxygenation in patients undergoing coronary artery bypass grafting. Anesth Analg 84 (1997) 950-957
26. Welch M., Newstead C.G., Smyth J.V., et al. Evaluation of dopexamine hydrochloride as a renoprotective agent during aortic surgery. Ann Vasc Surg 9 (1995) 488-492
27. MacGregor D.A., Butterworth J.F., Zaloga C.P., et al. Hemodynamic and renal effects of dopexamine and dobutamine in patients with reduced cardiac output following coronary artery bypass grafting. Chest 106 (1994) 835-841
28. Renton M.C., and Snowden C.P. Dopexamine and its role in the protection of hepatosplanchnic and renal perfusion in high-risk surgical and critically ill patients. Br J Anaesth 94 (2005) 459-467
29. Bach F., Grundmann U., Bauer M., et al. Modulation of the inflammatory response to cardiopulmonary bypass by dopexamine and epidural anesthesia. Acta Anaesthesiol Scand 46 (2002) 1227-1235
30. Bellomo R., Chapman M., Finfer S., et al., Australian and New Zealand Intensive Care Society (ANZICS) Clinical Trials Group. Low-dose dopamine in patients with early renal dysfunction. A placebo-controlled randomised trial. Lancet 356 (2000) 2139-2143
31. Juste R.N., Panikkar K., and Soni N. The effects of low-dose dopamine infusions on haemodynamic and renal parameters in patients with septic shock requiring the treatment with noradrenaline. Intensive Care Med 24 (1998) 564-568
32. Marik P.E. Low-dose dopamine. A systemic review. Intensive Care Med 28 (2002) 877-883
33. Kellen M., Aronson S., Roizen M.F., et al. Predictive and diagnostic tests of renal failure. A review. Anesth Analg 78 (1994) 134-142
34. MacGregor D.A., Smith T.E., Prielipp R.C., et al. Pharmacokinetics of dopamine in healthy male subjects. Anesthesiology 92 (2000) 338-346
35. Carey R.M., Siragy H.M., Ragsdale N.V., et al. Dopamine-1 and dopamine-2 mechanisms in the control of renal function. Am J Hypertens 3 (1990) 59S-63S
36. Vyhnanek F., Vanecek M., Helfert I., et al. The effects of hydrocortisone and dopamine on circulatory alterations in experimental acute endotoxin shock in dogs. Z Exp Chir 11 (1978) 322-327